Retrospective analysis of treatment responses to enfortumab vedotin combined with pembrolizumab (EVP) based on FGFR2/3 alterations in patients (pts) with advanced urothelial carcinoma (aUC).
Mamta Parikh(UC Davis Comprehensive Cancer Center), Nataliya Mar(University of California, Irvine), Amanda Macaraeg(University of California, Irvine), Steven N. Seyedin(University of California, San Francisco), Suzanne M. Dufault(University of California, San Francisco), Terence W. Friedlander(University of California, San Francisco), M. Semaan(University of California, San Francisco), Alexandra Drakaki(UCLA Jonsson Comprehensive Cancer Center), Neda Hashemi-Sadraei(University of New Mexico), Ali Raad(Cancer Clinic), Kevin R. Reyes(University of California, San Francisco), Dimitrios Stefanoudakis(APLA Health)
Cited by 0
Related Papers
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
|JAMA Oncology|2017|846
Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer
|International Journal of Cancer|2013|127
Circulating Tumor Cells as Potential Biomarkers in Bladder Cancer
|The Journal of Urology|2015|88